Qian S W, Burmester J K, Tsang M L, Weatherbee J A, Hinck A P, Ohlsen D J, Sporn M B, Roberts A B
Laboratory of Chemoprevention, NCI, National Institutes of Health, Bethesda, Maryland 20892-5055, USA.
J Biol Chem. 1996 Nov 29;271(48):30656-62. doi: 10.1074/jbc.271.48.30656.
Transforming growth factor-beta (TGF-beta) isoforms have differential binding affinities for the TGF-beta type II receptor (TbetaRII). In most cells, TGF-beta1 and TGF-beta3 bind to TbetaRII with much higher affinity than TGF-beta2. Here, we report an analysis of the effect of TGF-beta structure on its binding to TbetaRII by using TGF-beta mutants with domain deletions, amino acid replacements, and isoform chimeras. Examination of the binding of TGF-beta mutants to the recombinant extracellular domain of TbetaRII by a solid-phase TGF-beta/TbetaRII assay demonstrated that only those TGF-beta mutants containing the C terminus of TGF-beta1 (TGF-beta1-(Delta69-73), TGF-beta1-(Trp71), and TGF-beta2/beta1-(83-112)) bind with high affinity to TbetaRII, similar to native TGF-beta1. Moreover, replacement of only 6 amino acids in the C terminus of TGF-beta1 with the corresponding sequence of TGF-beta2 (TGF-beta1/beta2-(91-96)) completely eliminated the high affinity binding of TGF-beta1. Proliferation of fetal bovine heart endothelial (FBHE) cells was inhibited to a similar degree by all of the TGF-beta mutants. However, recombinant soluble TbetaRII blocked the inhibition of FBHE cell proliferation induced by TGF-beta mutants retaining the C terminus of TGF-beta1, consistent with the high binding affinity between these TGF-beta molecules and TbetaRII. It was further confirmed that the TGF-beta2 mutant with its C terminus replaced by that of TGF-beta1 (TGF-beta2/beta1-(83-112)) competed as effectively as TGF-beta1 with 125I-TGF-beta1 for binding to membrane TbetaRI and TbetaRII on FBHE cells. These observations clearly indicate that the domain in TGF-beta1 responsible for its high affinity binding to TbetaRII, both the soluble and membrane-bound forms, is located at C terminus of the molecule.
转化生长因子-β(TGF-β)亚型对TGF-β II型受体(TβRII)具有不同的结合亲和力。在大多数细胞中,TGF-β1和TGF-β3与TβRII的结合亲和力远高于TGF-β2。在此,我们报告了一项通过使用具有结构域缺失、氨基酸替换和亚型嵌合体的TGF-β突变体来分析TGF-β结构对其与TβRII结合影响的研究。通过固相TGF-β/TβRII分析检测TGF-β突变体与重组TβRII细胞外结构域的结合,结果表明,只有那些包含TGF-β1 C末端的TGF-β突变体(TGF-β1-(Δ69 - 73)、TGF-β1-(Trp71)和TGF-β2/β1-(83 - 112))与TβRII具有高亲和力结合,类似于天然TGF-β1。此外,仅将TGF-β1 C末端的6个氨基酸替换为TGF-β2的相应序列(TGF-β1/β2-(91 - 96))就完全消除了TGF-β1的高亲和力结合。所有TGF-β突变体对胎牛心脏内皮(FBHE)细胞增殖的抑制程度相似。然而,重组可溶性TβRII阻断了由保留TGF-β1 C末端的TGF-β突变体诱导的FBHE细胞增殖抑制,这与这些TGF-β分子和TβRII之间的高结合亲和力一致。进一步证实,其C末端被TGF-β1的C末端取代的TGF-β2突变体(TGF-β2/β1-(83 - 112))与TGF-β1一样有效地竞争125I-TGF-β1与FBHE细胞膜上TβRI和TβRII的结合。这些观察结果清楚地表明,TGF-β1中负责其与可溶性和膜结合形式的TβRII高亲和力结合的结构域位于分子的C末端。